Press Releases

July 31, 2020

One Lambda Announces At-Home Specimen Collection for Transplant Patients

Post-transplant patients at risk for COVID-19 can now coordinate remote post-transplant testing

WEST HILLS, Calif. (July 31, 2020) – One Lambda, Inc., part of Thermo Fisher Scientific and leading producer of in vitro diagnostic products for the HLA transplant community, announced a collaboration with transplant centers across the U.S. to facilitate a solution for immunosuppressed transplant patients to receive post-transplant testing in the their home. The program is part of the company’s efforts to better support their transplant patient population against the pandemic.
"Since the very beginning, we have been dedicated to improving the lives of transplant patients and their families. During this crisis, we’re pleased to provide a new way for patients to safely adhere to their testing plan at home."
Nicole Brockway | President, President of the Transplant Diagnostics Division, Thermo Fisher Scientific

 

The home-based blood draw service for human leukocyte antigen (HLA) antibody testing will be available to all patients who prefer to continue their post-transplant testing plan without the need to travel to their usual blood collection site. Working with their transplant team, patients can schedule an appointment for a blood draw at their home with a trained mobile phlebotomist.

“Since the very beginning, we have been dedicated to improving the lives of transplant patients and their families. During this crisis, we’re pleased to provide a new way for patients to safely adhere to their testing plan at home,” said Nicole Brockway, president of transplant diagnostics for Thermo Fisher Scientific. “This service will help reduce each patient’s exposure to COVID-19 while still allowing us to provide continuity in their post-transplant monitoring.”

After transplantation, patients undergo recurrent blood draws at labs, hospitals or dialysis centers to monitor the health of their transplanted organ.

Unfortunately, many transplant patients are avoiding regularly scheduled visits to testing centers during the COVID-19 pandemic. Due to their prescribed immunosuppressive drug regimens, these patients are considered high risk and are often advised by healthcare providers to take extra precautions to reduce their potential exposure to the virus.

As the global leader in transplant diagnostics for over thirty-five years, Thermo Fisher is committed to improving the lives of patients worldwide by driving innovation and delivering quality products. The company’s comprehensive product portfolio includes a broad range of Antibody Detection assays, post-transplant monitoring solutions including the novel Molecular Microscope Diagnostic System, HLA Typing products, laboratory instrumentation and software, and industry-leading customer support.

Patients and clinicians interested in at-home specimen collection for ongoing post-transplant monitoring may visit www.onelambda.com for more information.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue exceeding $25 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, improving patient diagnostics and therapies or increasing productivity in their laboratories, we are here to support them. Our global team of more than 75,000 colleagues delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services and Patheon. For more information, please visit www.thermofisher.com.

Follow us:  
Facebook LinkedIn Twitter